Industry

DUBLIN–(BUSINESS WIRE)–The “Biochips Market, By Product, By Application, By Substrate Materials, By Technology, By End-Use, and By Region Forecast to 2030” report has been added to ResearchAndMarkets.com’s offering. The global biochip market size is expected to reach USD 34.35 Billion in 2030 and register a revenue CAGR of 11.5% over the forecast period, according to … [Read more…]

DNA Script selected from 250 French companies to receive top award SOUTH SAN FRANCISCO, Calif. & PARIS–(BUSINESS WIRE)–#DNASynthesis–DNA Script, a world leader in Enzymatic DNA Synthesis (EDS) for DNA on demand, won the Grand Prize Trophy at the 2022 Future Unicorns Awards, whose ceremony took place on September 15, 2022, at the Bourrienne Hotel (Paris). … [Read more…]

CHARLESTON, W.Va.–(BUSINESS WIRE)–Starting this fall, students at the University of Charleston, West Virginia (UCWV) will study human anatomy in 3D, with the launch of a dedicated virtual reality (VR) lab, through a partnership with Perspectus, Inc., a Colorado-based virtual and mixed reality technology firm. “We are excited to offer virtual reality technology to enhance student … [Read more…]

ST. LOUIS–(BUSINESS WIRE)–Reinsurance Group of America, Incorporated (NYSE: RGA) (the “Company”) announced today that it has priced an aggregate principal amount of $700 million of 7.125% fixed-rate reset subordinated debentures due 2052 (the “2052 Debentures”) pursuant to a public offering. Wells Fargo Securities, LLC, BofA Securities, Inc., HSBC Securities (USA) Inc., J.P. Morgan Securities LLC, … [Read more…]

— Veklury is Now Recommended by the WHO for Use in Both Non-Severe COVID-19 Patients at the Highest Risk of Hospitalization and Patients with Severe COVID-19 — FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today announced updates to the World Health Organization’s (WHO) Therapeutics and COVID-19: living guideline, which now conditionally recommends Veklury® (remdesivir) … [Read more…]

SEATTLE–(BUSINESS WIRE)–Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the pricing of a firm commitment underwritten public offering of 3,600,000 shares of its common stock at a public offering price of $2.00 per share (the “Offering”). The aggregate gross proceeds from the Offering are expected to total … [Read more…]

– Oral poster showcasing positive results from Revance’s Phase 2 JUNIPER clinical trial, which demonstrated long-term efficacy and safety with DAXXIFY™ for the treatment of upper limb spasticity (ULS) in adults after stroke or traumatic brain injury – Study results indicate that DAXXIFY™ at the 500U dose is effective and well tolerated for treating adult … [Read more…]

New assays for Epstein-Barr virus (EBV) and human herpesvirus 6 (HHV-6) expand menu to now 16 available CE-IVD assays Improved multiple-target assay for respiratory diseases in development; new dual-target SARS-CoV-2 design enables faster clinical decisions Multiplex assay for detection of monkeypox planned to be made available in 2022 HILDEN, Germany & GERMANTOWN, Md.–(BUSINESS WIRE)–QIAGEN N.V. … [Read more…]

NASHVILLE, Tenn.–(BUSINESS WIRE)–Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings (“Revance” or the “Company”), today announced the closing of its previously announced underwritten public offering of 9,200,000 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 1,200,000 additional shares, … [Read more…]

— Combined Company to Trade on Nasdaq Under Ticker “SYRS” — — Syros Announces 1-for-10 Reverse Stock Split of Common Stock — CAMBRIDGE, Mass. & BEDMINSTER, N.J.–(BUSINESS WIRE)–Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. (NASDAQ:TYME) today announced the results of the … [Read more…]